Display options
Cite
Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011;13(2):119-30doi: 10.1007/s11940-010-0111-8.
Distad, B. J., Amato, A. A., & Weiss, M. D. (2011). Inflammatory myopathies. Current treatment options in neurology, 13(2), 119-30. https://doi.org/10.1007/s11940-010-0111-8
Distad, B Jane, et al. "Inflammatory myopathies." Current treatment options in neurology vol. 13,2 (2011): 119-30. doi: https://doi.org/10.1007/s11940-010-0111-8
Distad BJ, Amato AA, Weiss MD. Inflammatory myopathies. Curr Treat Options Neurol. 2011 Apr;13(2):119-30. doi: 10.1007/s11940-010-0111-8. PMID: 21222061.
Copy Download .nbib Format: NLM
Share it on

Curr Treat Options Neurol. 2011 Apr;13(2):119-30. doi: 10.1007/s11940-010-0111-8.

Inflammatory myopathies.

Current treatment options in neurology

B Jane Distad, Anthony A Amato, Michael D Weiss

Affiliations

  1. Department of Neurology, Neuromuscular Division, University of Washington, School of Medicine, Seattle, WA, 98195, USA, [email protected].

PMID: 21222061 DOI: 10.1007/s11940-010-0111-8

Abstract

OPINION STATEMENT: The mainstay of treatment for the idiopathic inflammatory myopathies currently and traditionally has been therapeutics aimed at suppressing or modifying the immune system. Most therapies being used are directed towards polymyositis (PM) and dermatomyositis (DM), as there is yet to be efficacious treatment of any kind for inclusion body myositis (IBM), However, there are few randomized controlled studies supporting the use of such therapies even in PM and DM. Even in the absence of controlled studies, oral corticosteroids (in particular high-dose prednisone) continue to be the first-line medications used to manage these conditions. Second-line therapies include the addition of chronic, steroid-sparing immunosuppressive drugs such as azathioprine, methotrexate, cyclosporine, cyclophosphamide, and mycophenolate mofetil. These drugs are typically added when patients are on corticosteroids for an extended period or when the disease is refractory. Such medications often allow corticosteroid dosages to be reduced, but monitoring is required for their own side effects, such as bone marrow suppression, kidney dysfunction, and respiratory concerns. Small controlled studies also support the role of intravenous immunoglobulin therapy as an alternative therapy, particularly for DM, though the cost of this treatment is sometimes prohibitive. Rituximab, a monoclonal antibody that depletes B cells, has also shown efficacy in uncontrolled studies in DM and holds promise for the treatment of this disease. Other promising immunotherapies currently under study are inhibitors of interferon-α and tumor necrosis factor-α. Unfortunately, though a number of immunomodulatory treatments have been investigated in IBM, none has convincingly demonstrated benefit.

References

  1. Ann Neurol. 2002 Mar;51(3):369-72 - PubMed
  2. Neurology. 1997 Mar;48(3):712-6 - PubMed
  3. J Rheumatol. 2000 Oct;27(10):2498-503 - PubMed
  4. Arthritis Rheum. 1981 Jan;24(1):45-8 - PubMed
  5. Arch Neurol. 1991 Jan;48(1):26-30 - PubMed
  6. Neurology. 2005 Dec 13;65(11):1782-7 - PubMed
  7. Medicine (Baltimore). 1993 Jul;72(4):225-35 - PubMed
  8. Arthritis Rheum. 2007 May 15;57(4):694-702 - PubMed
  9. Neuromuscul Disord. 2004 May;14(5):337-45 - PubMed
  10. Clin Rev Allergy Immunol. 2005 Dec;29(3):255-69 - PubMed
  11. N Engl J Med. 1975 Feb 13;292(7):344-7 - PubMed
  12. Neuromuscul Disord. 1999 Jun;9(4):239-46 - PubMed
  13. Arch Otolaryngol Head Neck Surg. 1992 Mar;118(3):313-7 - PubMed
  14. Muscle Nerve. 1991 May;14(5):470-3 - PubMed
  15. J Neurol. 2000 Jan;247(1):22-8 - PubMed
  16. N Engl J Med. 1986 Feb 6;314(6):329-34 - PubMed
  17. Eur Neurol. 2008;59(3-4):159-63 - PubMed
  18. J Neurol. 1989 Dec;236(8):489-90 - PubMed
  19. Arthritis Rheum. 2005 Feb;52(2):601-7 - PubMed
  20. Arch Neurol. 1991 Dec;48(12):1229-34 - PubMed
  21. J Neurol. 2003 Apr;250(4):480-5 - PubMed
  22. Neurology. 2003 Jul 22;61(2):260-2 - PubMed
  23. Neurology. 1993 May;43(5):876-9 - PubMed
  24. Arch Dermatol. 2007 Jun;143(6):763-7 - PubMed
  25. Neurology. 2001 Feb 13;56(3):323-7 - PubMed
  26. Muscle Nerve. 2010 Feb;41(2):185-90 - PubMed
  27. Scand J Rheumatol. 2010;39(1):88-92 - PubMed
  28. Ann Neurol. 2005 May;57(5):664-78 - PubMed
  29. Arthritis Rheum. 2013 Feb;65(2):314-24 - PubMed
  30. Curr Opin Neurol. 2004 Oct;17(5):561-7 - PubMed
  31. Arthritis Rheum. 2002 Feb;46(2):467-74 - PubMed
  32. J Neurol Neurosurg Psychiatry. 2009 Oct;80(10):1060-8 - PubMed
  33. J Neurol Neurosurg Psychiatry. 2001 May;70(5):569-73 - PubMed
  34. Neurology. 2004 Aug 24;63(4):718-20 - PubMed
  35. Am J Med. 1993 Apr;94(4):379-87 - PubMed
  36. J Rheumatol. 2000 Dec;27(12):2855-9 - PubMed
  37. J Neurol Sci. 1989 Dec;94(1-3):181-92 - PubMed
  38. Rheumatology (Oxford). 2007 Jan;46(1):124-30 - PubMed
  39. N Engl J Med. 1993 Dec 30;329(27):1993-2000 - PubMed
  40. Neurology. 1995 Jul;45(7):1302-4 - PubMed
  41. Neurology. 2002 Apr 9;58(7):1081-7 - PubMed
  42. Ann Neurol. 1996 Oct;40(4):581-6 - PubMed
  43. Ann Intern Med. 1980 Mar;92(3):365-9 - PubMed
  44. N Engl J Med. 1975 Feb 20;292(8):403-7 - PubMed

Publication Types